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Resistance to a wide variety of common antimicrobials is observed among clinical strains designed as 
extended spectrum β-lactmase (ESBL) producers. They produce enzymatic protein which inactivates 
efficiently oxyimino cephalosporin and constitutes a serious global health concern that has complicated 
treatment strategies. Many studies report high prevalence of ESBL producers among Gram negative 
bacilli. The aim of this work was to identify the presence of TEM, SHV and CTX-M families in these 
strains which were initially screened by phenotypic method. Gram negative bacilli resisting third or four 
generation cephalosporin were isolated during anti-biogram study. The presence of ESBL positivity 
was detected using the double disk synergy test. Minimal inhibitory concentrations (MICs) of ceftriazon 
for any strain were determined using E-test manufacturing protocol. Polymerase chain reaction (PCR) 
analysis for β-lactamase (bla) genes of TEM, SHV and CTX-M family was carried out using designed 
primers in 171 ESBL isolates producers. Among 259 Gram negative bacilli collected, 171 (66, 02%) 
exhibited ESBL producers’ profile. Urine samples constitute major source of ESBL producers. The 
highest prevalence of ESBL was observed in Escherichia coli (75, 50%). Among ESBL isolates 
producers, gene prevalence of bla-CTX-M (65, 49%) was highest, followed by bla-TEM (25, 73%) and bla-
SHV (18, 71%) in the present study. The frequency of ESBL producing strains among clinical isolates 
has been steadily increased. Continual drug resistance surveillance and molecular characteristics of 
ESBL isolates are necessary to guide the appropriate and judicious antibiotic use. 
 





Loss of antibacterial proprieties is now established for 
many antibiotics substances, particularly those of β-lactam 
class with regard to therapy failure observed in clinical 








mechanism of resistance is based on the production of β-
lactamases, enzymatic proteins, which hydrolyze β-
lactam ring (Webb, 1984) described several decades 
later (Abraham and Chain, 1940). In Gram negative 
bacilli, β-lactamases are produced and stocked in 
periplasmic compartment (Frère, 1998). According to 
catalytic mechanism, two families of β-lactamases are 
distinguished (Frère, 1995; Matagne et al, 1999). The 
serine β-lactamases carrying an amino-acid residue-seryl 
in the catalytic site and metallo-β-lactamases are needed 
for their catalytic activity in the presence of metallic ion in 
active site. According to their molecular structure, β-
lactamases are organized in class A, C, D and B 
enzymes (Ambler, 1975, 1978, 1980). Serine β-lacta-
mases consist of class A, C and D enzymes while 
metallo-β-lactamases consist of class B enzymes. Our 
study concerns class A enzymes which consist of the 
following groups: Temoneira (TEM), sulfidrhyl-variable 
(SHV), cefotaximase (CTX-M), pseudomonas extended 
resistance (PER). Those chromosomal or plasmid-
mediated enzymes are either penicillinases (TEM-1/2 and 
SHV-1) hydrolyzing penicillins, first and second 
generation cephalosporins or extended-spectrum-β-
lactamases (ESBL). Extended-spectrum-β-lactamases 
(TEM-3, SHV-2 and CTX-M), a form of β-lactamases, 
hydrolyzing third generation of cephalosporins (like oxy-
iminocephalosporins); detected since 1983 (Knothe et al., 
1983) are now worldwide reported. ESBL, detected at 
first in Klebsiella pneumoniae and Escherichia coli 
(Medeiros, 1984; Bradford, 2001), is now fully spread in a 
number of enterobacterial spices and other kind of 
bacterial isolates, often responsible for nosocomial 
epidemic outbreak. Therapy failure due to these fasti-
dious strains makes clinicians to prescribe more and 
more carbapenem antibiotics for fighting resistant strains 
resisting all class of antibiotic (Queenan and Bush, 
2007; Poirel et al., 2007). Therefore, a research on how 
to control ESBL epidemiology is a noble undertaking. 
Molecular studies leading in many countries have allowed 
getting more information on genetic matrix and molecular 
types. In Turkey, a survey of Klebsiella spp. from 
intensive care units from eight hospitals showed that 58% 
of 193 isolates harbored ESBLs (Gunseren et al., 1999). 
In Chicago, infections with TEM-type ESBLs particularly 
TEM-10, TEM-12, and TEM-26 were reported since 1996 
(Schiappa et al., 1996). Boyd et al. (2004) in their study, 
described CTX-M-type ESBLs in United States and 
Canada. CTX-M-12 was first detected in Kenya by Kartali 
et al. (2002) (Kartali et al., 2002). Characterization of 
ESBLs from South Africa revealed the types of TEM and 
SHV (especially SHV-2 and SHV-5) (Hanson et al., 
2001). In Burkina Faso, bla SHV and bla TEM were first 
reported in 2004  in community  medical  center  (Zeba et 




al., 2004). Microbial drug resistances based on ESBL 
were reported (Karou et al., 2009), but there is no study 
on determining the different types of gene encoding. 
Therefore, this study aimed to contribute to clear bacterial 
resistance epidemiology by establishing genetic profile of 
Gram negative bacilli that resist oxy-iminocephalosporins 
and exhibit extended-spectrum β-lactamase at University 
Hospital Center Yalgado, Ouedraogo.  
 
 
MATERIALS AND METHODS 
 
Clinical specimens and strains 
 
Bacterial strains collected during a prospective study from July 
2009 to March 2012 were Gram negative bacilli that resist third 
generation of cephalosporin. They were isolated and diagnosis 
analysis of biological specimens was done. Different clinical 
specimens such as blood, urine, pus, ascitic fluid, peritoneal fluid, 
stool and rachis fluid samples were collected from different 
hospitalized patients. Samples were taken from infected patients 
who presented infectious evident symptoms like fever and purulent 
urine. Isolates were identified using conventional method (Kelly et 
al., 1985). Identification of isolates was achieved using API 20E test 
trips (BioMerieux S.A., Marcy l’Etoile, France).  
 
 
Antibiotic susceptibility testing and ESBL detection 
 
Antibiotic susceptibility was tested by disk diffusion method (Bauer, 
1966), with antibiotic disks used to test Gram negative bacilli 
particularly monobactam: Aztreonam (30 µg), third generation 
cephalosporin like cefotaxim (30 µg), ceftriaxon (30 µg), ceftazidim 
(30 µg), and fourth generation cephalosporins: cefepim (30 µg). 
Antibiotics were tested on Petri plates containing Muller Hinton 
agar. Measurements of inhibition area determine the clinical 
categories (CA-SFM, 2010; 2011; 2012). Isolates that were resistant 
to at least one of the antibiotics in clinical test, using NCCLS 
methods (NCCLS, 2000) were collected, purified and conserved at -
80°C for furthers analysis. In order to screen ESBL phenotypical 
profile, isolates were submitted for synergy test (Jarlier et al., 1988) 
between third generation of cephalosporins disks (cefotaxime or 
ceftazidime) and amoxicillin plus clavulanic acid.  
In addition, MICs of ceftriaxone, antibiotic frequently used in 
clinical routine in our sanitary centers was performed as recom-
mended by guide E-test AB BIODISK. 
 
 
Molecular characterization of ESBL producing-isolates 
 
All isolates which were positive for synergy test were screened in 
order to detect β-lactamase encoding genes for bla TEM, SHV and 
CTX-M families by previously described PCR protocols (Olivier et 
al., 2002; Pagani et al., 2003). DNA template was prepared from 
purified bacteria grown overnight at 37°C on Muller Hinton agar 
plates. Crude DNA extracts were obtained by suspending a colony 
in 100 µl of purified water and boiling at 95°C for 10 mn (Munday et 
al.; 2004). Mixed PCR for one reaction has the following 
components: 5 µl of Green buffer 5X; 1 µl of each Primer 10µM; 
0.65µl of dNTPs 10 mM; 0.12 µl of Gotaq 0.5 U/µl and 15.25 µl of 
purified water. Reaction volume is completed to 25 µl with 2 µl of 
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Table 1. Primers used for amplification of BlaTEM, SHV and CTXM genes. 
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Figure 1.  Detection of ESBL Escherichia coli producer on plate. a) Pure colonies of Escherichia coli. b) Antibiogram of Escherichia coli. 




DNA template. Primers supplied by Promega according to each β-
lactamase gene type are in Table 1. PCR was carried out under the 
following conditions on SensoQest Labcycler, GmbH, Germany: 
initial denaturation step at 96°C for 5 min, followed by 35 cycles 
consisting of denaturation at 96°C for 1 min, annealing at 58°C, 
60°C and 50°C for TEM, SHV and CTX-M at 1 min, primer 
extension at 72°C for 1 min and final extension for 10 min.  
Migration of PCR products watched by Green buffer (Eugentec) 
during 30 min at 80 V was performed on agar gel of 1%, prepared 





Bacterial strains and antibiotic susceptibility testing 
 
During this study, 259 Gram negatives bacilli which resist 
at least one- third or fourth generation of cephalosporins 
or monobactam were collected from different samples 
(Figure 2). For all the strains collected, diameters of 
inhibiting area around oxy-iminocephalosporins disc were 
less than 16 mm. Resisting bacterial species isolated 
were about quantitative importance: 132 Escherichia coli, 
43 Klebsiella pneumoniae, 34 Pseudomonas aeruginosa, 
24 Enterobacter sp.,11 Citrobacter spp 7 Accinetobacter 
baumannii, 6 Proteus mirabilis, and 1 Salmonella typhi. 
Extended-spectrum β-lactamase phenotype screening 
showed that 171 strains (66, 02%) were positive for 
synergy test, suggesting that they were extended-
spectrum- β-lactamases-producers (Figure 1). The 
highest proportion (62.57%) of their strains was isolated 
from urine samples. 
The MICs of ceftriaxone determined by E-test were less 
than 50, 100 and 256 µg/ml for 81, 57, 55.26 and 39.74% 
isolates (Figure 2). MICs of ceftriaxone for 73.33% of E. 
coli (22/30) and 80% of K. pneumoniae were less than 64 
µg/ml. Among the positive isolates for synergy test, 
bacterial species were spread as follows: 99 E. coli (that 
is, 75% of E. coli), 28 K. pneumonia (that is, 65.11% of K. 
pneumoniae), 19 P. aeruginosa (55.88%) 15 enterobacter 
sp. (62,50%), 4 citrobacter sp(36,36%), 2 acinetobacter 
baumannii, 3 Proteus mirabilis, 1 Salmonella typhi. 
Except P. aeruginosa and Accinetobacter baumannii, the 
rest isolates belong to enterobacterial family. The study 
focused on bacterial resistance and no process determined 
community or hospital origin of isolates.  
 
 
Polymerase chain reaction: Amplification of bla 
genes  
 
In the electrophoresis of PCR products realized with DNA 
ladder, positive and negative control showed bands as 
previously around 875 bp for bla SHV and 1000 bp for bla 
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Figure 2.  a. Sensitive pattern of Escherichia coli Ceftriazon, CMI = 96 µg/ml. b) Sensitive 






Figure 3. Agarose gel of CTX-M PCR products. M, Marker of molecular weight 
(GeneRuler 100 bp DNA ladder). Number 1-5 correspond to samples: 1 = 45H, 2 = 219P, 




isolates (exhibiting extended –spectrum β-lactamase 
phenotype) showed that 112 strains (65.49%) were 
positive for CTX-M screening; 44 stains (25.73%) for 
TEM screening and 32 strains (18.71%) for SHV. In all 
the bacterial species, some associations were found 
between the three types of bla genes. Eleven (11) 
isolates carried bla TEM, SHV, CTX-M at the same time. 
Finally, 134 isolates (78, 36%) were positive for β-
lactamase gene screening and 37 strains did not carry 
any of their β-lactamase genes. Repartition of β-latamase 
gene type among bacterial species was established.  
Among 99 E. coli investigated, 11.11% carried single 
bla TEM; 7.07% carried bla SHV and 48.48% carried 
single bla CTX-M. 5. 05% harbored bla TEM linked to bla 
SHV; 5.05% carried bla TEM linked to bla CTX-M; 5.05% 
carried bla SHV with bla CTX-M and 6.06% carried both 
bla TEM, bla SHV and bla CTX-M. 70.70% of E. coli 
carried at least bla CTX-M or CTX associated with other 
bla genes. Among 28 K. pneumonia screened for bla 
genes, 14.28% carried single bla TEM; 10. 71% carried 
bla SHV; 25% carried single bla CTX-M and 10.71% 









Table 2. Spread of bla-genes among bacterial spices. 
 
Bacterial species Number TEM SHV CTX-M TEM -SHV- CTXM 
Escherichia coli 99 25 20 70 6 
Klebsiella pneumoniae 28 9 4 12 1 
Enterobacter sp. 15 3 5 10 2 
Pseudomonas aeruginosa 19 5 2 12 2 
Citrobacter sp. 4 1 1 3 0 
Acinetobacter baumannii 2 1 0 2 0 
Proteus mirabilis 3 0 0 2 0 
Salmonella typhi 1 0 0 1 0 




carried bla TEM, bla SHV and bla CTX-M. 42.85% 
carried at least bla CTX-M.  
From 15 Enterobacter sp. screened, 13.33% of strains 
carried bla SHV, 20% carried bla TEM associated with 
other genes, 20% carried bla SHV in association with bla 
CTX-M. 66.66% carried either bla CTX-M or CTX-M 
linked to other genes. Among 19 strains of P. aeruginosa, 
10.52% harbored bla TEM, 31.57% carried bla CTX-M. 
21.05% of strains carried bla TEM associated with bla 
CTX-M, while 5.26% carried bla CTX-M associated with 
bla SHV and 10.52% of strains harbored bla TEM, bla 
CTX-M and bla SHV. At least, bla CTX-M was found in 
52.63% of P. aeruginosa screened. The distribution of bla 
genes among the bacterial species is shown in Table 2. 
Our study has noted that patients of all age were 
affected by bla gene and ESBL (Table 3). From the 
results, 11.36, 9.37% and 5.35% of bla TEM, SHV and 
CTX-M, respectively were found on patients of less than 
1 year old. For children of less than five years old, 22, 
28.12 and 14.28% of bla TEM, SHV and CTX-M were 
found. According to sexual repartition, 40,90%, 50% and 
44,64% of bla TEM, SHV and CTX-M were found in 
female group, while 65.90, 50 and 55.35% of bla TEM, 





The most important part of our strains was resistant to 
cefotaxim, ceftriaxon and aztreonam. The rate of 
resistance to those antibiotics was globally greater than 
50% of isolates. Bacteriological and susceptibility study at 
Tunis University Hospital reported rates of resistance to 
β-lactam by enterobacterial at 57.90% (Larabi et al., 
2003). PCR results have shown that most proportion of 
strains carried bla CTX-M which are ESBLs (Bonnet, 
2004). There is high possibility that bla TEM and bla SHV 
are found in ESBL because producing stains were 
resistant to oxi-iminocephalosporin (Livermore, 2008). 
ESBLs have become a widespread serious problem. 
These enzymes are becoming increasingly expressed by 
many strains of pathogenic bacteria with a potential for 
dissemination. The presence of ESBL compromises the 
activity of wide-spectrum antibiotics creating major thera-
peutic difficulties with a significant impact on the outcome 
of patients. The continuous emergence of ESBLs presents 
diagnostic challenges to the clinical microbiology labora-
tories. 
In this study, urine represent samples indexed as 
extended-spectrum β-lactamase isolates producing source. 
Similar observations are reported in others studies 
(Shanthi and Sekar, 2010; Iraj and Nilufar, 2011; Saba et 
al., 2012). Invasive treatment using catheter at hospital 
centers often explains high prevalence of urinary infections 
(Cantón et al., 2008). In addition, in community, people 
practice auto medication with antibiotics that can select 
ESBLs isolates which may be carried at hospital notably 
in emergencies units and disseminated in other clinical 
offices (Mbutiwi et al., 2013). In this study, it was found 
that E.coli is frequently identified as ESBL producing 
isolate (Shanthi and Sekar, 2010; Abhilash et al., 2010; 
Umadevi et al., 2011). It is bacterial species, most 
adapted to and represented in digestive stratus and 
consequently receives plasmid-mediated gene from other 
bacteria.  
Phenotypic tests for ESBL detection only confirm if an 
ESBL is produced but cannot detect the ESBL subtype. 
Some ESBLs may fail to reach a level to be detected by 
disk diffusion tests but result in treatment failure in the 
infected patient. Nuesch-Inderbinen and Hachler (1996) 
reported that molecular methods appear sensitive, are 
expensive, time consuming and require specialized equip-
ment and expertise. However, definitive identification is 
possible only by molecular detection methods. 
There are so many types of β-lactamase like TEM, 
SHV, CTX, OXA, AmpC, etc, but majority of the ESBLs 
are derivatives of TEM or SHV or CTX-M enzymes and 
these enzymes are most often found in E. coli and K. 
pneumonia (Paterson and Bonomo, 2005). Keeping in 
view this fact, the current study investigated Gram 
negative bacilli among which E. coli and K. pneumoniae 
were most represented. The study aimed to look for the 
presence of TEM, SHV or CTX-M gene.  
From the results of the study, the three families of β- 
lactamase genes screened were found with high 
prevalence  of  CTX-M,  followed by TEM and  SHV. PCR




Table 3. Spread (number) of bla genes by sex/age on infected patients. 
 
Age (years) <1 1- 5-14 15 -25 ≥26 
          Sex 
Bla 
M F M F M F M F M F 
TEM 03 02 03 02 02 03 04 02 17 09 
SHV 01 02 02 04 03 00 02 03 08 07 




screening of 99 E. coli has shown that 25.25% harbored 
TEM gene, 20.20% harbored SHV gene and 70.70% 
harbored CTX-M gene. Of 28 K. pneumonia, 14.28% 
harbored TEM gene, 32.14% harbored SHV gene and 
42.85% harbored CTX-M gene. 20% of Enterobacter sp. 
harbored TEM gene, 33.33% harbored SHV gene and 
66.66% harbored CTX-M gene. 26.31% Pseudomonas 
aeruginosa harbored TEM gene, 10,52% harbored SHV 
gene and 63,15% harbored CTX-M gene. Livermore et 
al., stated in separate studies that the CTX-M gene is the 
most prevalent ESBL-encoding gene worldwide and is 
replacing TEM and SHV types as the predominant ESBL 
in many European and Asian countries (Livermore et al., 
2007; Bali et al., 2010). The high prevalence of CTX-M 
gene in our study is in concordance with the study of 
other authors (Vaida et al., 2010) who reported CTX-M-
encoding genes in the majority of E. coli (96%) and K. 
pneumoniae (71%) isolates showing ESBL phenotype. In 
our study, major part of the isolates carried more than 
one type of gene. Among E.coli , bla TEM, bla SHV and 
bla CTX-M matched with each other in the same 
proportion(5,05%). Among Klebsiella pneumonia, bla 
TEM associated with bla SHV in 10, 71% of strains. 6, 
43% isolates harbored all the three β lactamase genes. 
CTX-M is frequently associated with other β lactamase 
genes. According to Goyal et al., majority of strains 
(57.3%) harbored two or more ESBL genes. Bali et al. 
have observed in their study that 19.2% ESBL isolates 
carried more than one type of β lactamase genes (Goyal 
et al., 2009; Bali et al., 2010). The three types of bla gene 
were found within group of children of less than 5 years 
old. This fact is relevant for using antibiotics for viral 
infections, that are resistant (Bergus et al., 1996). The 
limitation of our study is the bacterial ecology which was 
not identified by any process. We were not able to know 
for some patients, if resistant bacteria were acquired in 





Our study has shown high prevalence of β-lactamases- 
isolates producers among clinical strains detected through 
analysis of biological samples collected in different units 
of University Hospital Center, Yalgado OUEDRAOGO. 
CTX-M type (ESBL) was mostly represented, followed by 
TEM and SHV β-lactamases. Escherichia coli, like in 
other several studies, was the strain that expressed 
ESBL frequently and can associate with more than one 
type. P. aeruginosa nosocomial, fastidious strain, known 
for producing PER currently harbored more and more 
CTX-M, TEM and SHV. This fact increases risk of ESBL 
dissemination between plasmid receptive strains or/and 
between clinical units. The present study has established 
that β-lactamin antibiotic except cephamycin and 
carbapenem (imipenem) was sensitive to ESBL. 
Diameters of inhibition area of oxy-iminocphalosporin 
(cefotaxim, ceftriazon, ceftazidim) for our isolates were 
seriously reduced, currently less than 20 mm. ESBL 
strains are usually multi-drug resistant. So, the practice of 
routine ESBL testing along with conven-tional 
antibiogram would be useful for all cases; it will help in 
theproper treatment of patients and also prevent further 
development of bacterial rug resistance. Molecular 
detection and identification of β- lactamases would be 
essential for a reliable epidemiological investi-gation of 
antimicrobial resistance. It is necessary to control hygiene 
and antibiotics consummation in hospital centers. 
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